Clinical trials: Cyclophosphamide, completed
Breast Cancer
Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer
The study hypothesis is that the new drug EndoTAG-1 will improve tumor volume reduction as measured by Magnetic Resonance Imaging when added to a standard chemotherapy regimen of weekly paclitaxel.
- Trial name
- EndoTAG-1 (NCT01537536)
- Testing
- EndoTAG-1
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Jules Bordet Institute
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.
- Trial name
- NCT00545714
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 33 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003032
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 25 sites in Canada
- Volunteers
- 224 people
- Sponsor
- NCIC Clinical Trials Group
Sarcoma
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
This study will examine the safety and effectiveness of stem cell transplantation for treating patients with sarcomas (tumors of the bone, nerves, or soft tissue).
- Trial name
- NCT00043979
- Testing
- F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
ANCA-associated Vasculitis
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.
- Trial name
- NCT05197842
- Testing
- BDB-001 injection, Cyclophosphamide, Glucocorticoids
- Where
- 22 sites in China
- Volunteers
- 93 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Total Marrow Irradiation for Refractory Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow irradiation before a donor umbilical cord blood or hematopoietic stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00686556
- Testing
- cyclophosphamide, cyclosporine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
HER2-Positive Breast Cancer
TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Both TCH (docetaxel/carboplatin/trastuzumab) and EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN…
- Trial name
- neoCARH (NCT03140553)
- Testing
- TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes.
- Trial name
- NCT00041119
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 527 sites in United States, South Africa
- Volunteers
- 3,871 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
This is a randomized, Phase III, open-label, multicenter study.
- Trial name
- TITAN (NCT00789581)
- Testing
- Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra)
- Where
- 70 sites in United States, Puerto Rico
- Volunteers
- 614 people
- Sponsor
- SCRI Development Innovations, LLC
Ewing's Sarcoma
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment.
- Trial name
- EW-1 (NCT02063022)
- Testing
- Standard treatment (as per protocol ISG SSG III), Intensified chemotherapy
- Where
- 14 sites in Italy
- Volunteers
- 278 people
- Sponsor
- Italian Sarcoma Group
Breast Cancer
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
This study will evaluate the effect of bevacizumab in combination with chemotherapy or endocrine therapy, as preoperative treatment, in participants with HER2 negative breast cancer.
- Trial name
- NCT00773695
- Testing
- Aromatase Inhibitor, Bevacizumab, Epirubicine
- Where
- 3 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia
Haploidentical NK-cell Infusion in Acute Myeloid Leukemia
Leukemia cells can be killed by natural killer (NK) from HLA-I mismatched donor. The proposed study plans to realize an adoptive anti-leukaemic immunotherapy by infusion of HLA-I mismatched NK cells to treat poor prognosis acute…
- Trial name
- NK (NCT01947322)
- Testing
- Allogenic NK cells infusion
- Where
- 4 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Myeloproliferative Disorders, Leukemia
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00068523
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or sequential administration of a taxane…
- Trial name
- NCT00431080
- Testing
- Docetaxel, Paclitaxel, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 478 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer, Breast Disease
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
The purpose of this study is to evaluate the association of zoledronic acid with standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER 2 positive.
- Conditions
- Breast Cancer, Breast Disease, Neoplasms, Neoplasms by Site
- Trial name
- NCT01472146
- Testing
- Zo-Nantax
- Where
- Brazil
- Volunteers
- 58 people
- Sponsor
- Susanne Crocamo
Breast Cancer, Non-Hodgkin's Lymphoma
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
The purpose of this study is to determine whether the drug mesna is able to block a series of chemical changes that occur in the blood of patients who receive the chemotherapy medicine doxorubicin.
- Trial name
- NCT01205503
- Testing
- Mesna, Saline, Doxorubicin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mara Chambers
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia…
- Trial name
- ZUMA-4 (NCT02625480)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 30 sites in United States, Belgium and 9 more
- Volunteers
- 95 people
- Sponsor
- Kite, A Gilead Company
Cognitive Impairment, Autoimmune Encephalitis
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
Most of patients with autoimmune encephalitis are left with permanent cognitive deficits of varying severity. The patients' life and career would be affected definitely by cognitive deficits.
- Trial name
- NCT03530462
- Testing
- rituximab, cyclophosphamide, Steroids
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Neoplasms, Breast
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel.
- Trial name
- NCT00524303
- Testing
- Trastuzumab, Paclitaxel, FEC75
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia
Despite substantial progress in the treatment pediatric acute leukemia a significant number of children will experience primary or secondary resistance to the treatment.
- Trial name
- NCT01025778
- Testing
- Clofarabine for remission induction, Etoposide for remission induction, Cyclophosphamide for remission induction
- Where
- Sweden
- Volunteers
- 7 people
- Sponsor
- Lund University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.